#United States #Washington D.C. #GLP-1 therapies #Landmark Science #ISPE 2025

Landmark Science at ISPE 2025

Landmark Science, Inc. is gearing up to take the stage at the upcoming International Society for Pharmacoepidemiology (ISPE) 2025 annual conference, scheduled from August 22 to 26 in Washington D.C. This year, the organization is highlighting its innovative research around real-world evidence, particularly focusing on the increasing use of GLP-1 receptor agonists and the implications for Medicare policy.

The new research features five compelling studies that delve into the characteristics of Medicare patients who are starting therapies involving GLP-1 receptor agonists, revealing critical insights into how these treatments are being utilized. One standout area of focus will be the patient demographics initiating Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction, which is increasingly relevant as GLP-1 medications extend their reach beyond diabetes management.

"Given the rapid integration of GLP-1s into clinical practice—from managing Type 2 diabetes to addressing broader health issues like cardiovascular risk, kidney disease, and obstructive sleep apnea—we’re witnessing a significant evolution in their usage among Medicare beneficiaries. However, data on how these therapies are utilized remains sparse. Real-world evidence is crucial to understanding prescribing behaviors and patient outcomes, which in turn informs care strategies and policymaking for Medicare recipients," shared Shivani Aggarwal, CEO of Landmark Science.

Puneet Budhiraja, Vice President of Analytics at Humbi AI by Innovaccer, emphasized the urgency for real-world data, stating, "As GLP-1s such as semaglutide gain traction in cardiometabolic treatment, there's an essential need to ensure that our data reflects accessibility, outcomes, and the potential disparities concerning who begins these treatments."

During ISPE 2025, Landmark’s epidemiologists will also introduce innovative methodologies that could significantly enhance evidence generation in regulatory decision-making processes. "Our research aims to highlight nuanced trends, transforming them into transparent, evidence-based findings that will ultimately promote the utility of real-world evidence in guiding future regulatory decisions," noted Aggarwal.

Key Highlights of Landmark's Research Presentations

• - Medicare Populations Using GLP-1 RAs: Two presentations detailing characteristics and outcomes of Medicare beneficiaries who initiate GLP-1 receptor agonists.
• - Wegovy for Cardiovascular Risk: Analysis specifically about Wegovy, offering insights into the patient demographic engaging with this treatment for cardiovascular protection.
• - Utilization of RWE in Regulatory Decisions: Insights on how real-world evidence can bolster regulatory submissions, enhancing understanding of its applicability and acceptance.
• - Framework for Regulatory Success: A new methodological framework will also be presented for applying regulatory guidelines to achieve successful submission outcomes.

Join Us at ISPE 2025

Attendees are encouraged to meet with Landmark Science at their booth at ISPE 2025 to delve deeper into the research, explore their abstracts, and participate in informative workshops and panel discussions.

For continuous updates, follow Landmark Science on their LinkedIn page or visit their official site. This conference represents not just the sharing of new research but a critical opportunity to influence healthcare decision-making in real-time, ensuring effective and equitable access to treatment options for patients.

For further inquiries, contact Landmark Science at [email protected] or visit their website at www.landmarkscience.com.

About Landmark Science, Inc.

Landmark Science, Inc. functions as a leader in life sciences, concentrating on real-world evidence and health outcomes research tailored to help patients. Their suite of research solutions merges expertise and innovative methodologies to serve various healthcare stakeholders effectively. Their specialties include advanced study designs that bolster regulatory submissions, therapeutic expertise, and comprehensive data landscaping.